Joanne O'KEeffe
Joanne O'KEeffe has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Gordon Ramage
Safeguarding Health through Infection Prevention (SHIP) Research Group, Research Centre for Health, School of Health and Life Sciences, Glasgow Caledonian University , Glasgow
1 shared publication Hafsa Abduljalil
Research Centre for Health, School of Health and Life Sciences Glasgow Caledonian University Glasgow UK
1 shared publication- Mark C. Butcher
Research Centre for Health, School of Health and Life Sciences Glasgow Caledonian University Glasgow UK
1 shared publication Neil Parry
Unilever R&D Wirral UK
1 shared publication- William Johnston
Oral Sciences Research Group, Glasgow Dental School, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
1 shared publication Yvonne Davies
Penrhos Bio Limited London UK
1 shared publication
Latest Publications
- Open Access
Mechanistic Investigations of a Novel Lactam Antifungal Agent Against Candida albicans
Candida albicans presents a major, yet underestimated challenge in clinical settings due to its increased resistance to treatment. This study intended to focus on the utility of a novel proprietary lactam molecule, a quorum sensing (QS) inhibitor, against C. albicans . We assessed isolate susceptibility to lactam treatment. In addition, RNA‐Seq was used to assess lactam‐induced transcriptional changes in phenotypically distinct C. albicans strains. The mechanistic basis of these transcriptional responses and a series of biochemical assays were performed using the reference strain SC5314. Our findings show that lactam influences multiple cellular processes, including cell wall integrity, efflux pump activity, oxidative stress responses and biofilm formation, with effects differing markedly between high and low biofilm formers. Vacuolation was observed with prolonged exposure to the lactam, and related genes in this process were identified and the phenotype confirmed. These results, supported by pathway analyses and mechanistic validation experiments, indicate that lactam's antifungal activity does not rely on a single mode of action. Rather, it appears to involve multiple mechanisms that vary across heterogeneous C. albicans isolates. These data indicate the potential therapeutic benefit of a novel fungicidal antifungal agent with broad‐spectrum activity.
Open AccessMechanistic Investigations of a Novel Lactam Antifungal Agent Against Candida albicans
Candida albicans presents a major, yet underestimated challenge in clinical settings due to its increased resistance to treatment. This study intended to focus on the utility of a novel proprietary lactam molecule, a quorum sensing (QS) inhibitor, against C. albicans . We assessed isolate susceptibility to lactam treatment. In addition, RNA‐Seq was used to assess lactam‐induced transcriptional changes in phenotypically distinct C. albicans strains. The mechanistic basis of these transcriptional responses and a series of biochemical assays were performed using the reference strain SC5314. Our findings show that lactam influences multiple cellular processes, including cell wall integrity, efflux pump activity, oxidative stress responses and biofilm formation, with effects differing markedly between high and low biofilm formers. Vacuolation was observed with prolonged exposure to the lactam, and related genes in this process were identified and the phenotype confirmed. These results, supported by pathway analyses and mechanistic validation experiments, indicate that lactam's antifungal activity does not rely on a single mode of action. Rather, it appears to involve multiple mechanisms that vary across heterogeneous C. albicans isolates. These data indicate the potential therapeutic benefit of a novel fungicidal antifungal agent with broad‐spectrum activity.